Covance Is Now Labcorp Drug Development

We are one global company innovating for millions – together, continuing to bring you more advanced medical breakthroughs.

Learn More

Lung Disease: Clinical Trials & Testing

Contact Us

Getting patients for clinical lung disease or disorder trials like asthma, COPD, cystic fibrosis, lower respiratory infections, or idiopathic pulmonary fibrosis (IPF), interstitial lung disease, and acute respiratory distress syndrome isn't easy. But we can get you the patients you need quickly. 

Expertise in specialized respiratory tests and analysis.

  • Pulmonary function testing, centralized spirometry and fractional exhaled nitric oxide (FeNO)
  • High-resolution computed tomography (HRCT)
  • Measures of exercise capacity, including six-minute walk test (6MWT) and cardiopulmonary exercise testing (CPET)
  • Sputum sampling and processing for biomarker assays, microbiology and cytology
  • Bronchoscopy with bronchoalveolar lavage (BAL)
  • Patient-reported outcomes (ePROs/diaries) and questionnaires

Clinical Trials

We've . . . 

  • Supported over 550 immune-mediated inflammatory disease (IMID) clinical trials in the past five years, including more than 90 asthma, 65 COPD, 20 CF and 20 IPF trials.
  • Managed at least 1 IPF trial per year since 2004.
  • Participated in more than 165 studies involving pediatric patients, equating to approximately 20% of all U.S. pediatric trials.

Laboratory Testing

  • Over 90 protocols for asthma and 65 for COPD. 
  • Patients represent the following countries: United States, United Kingdom, Poland, Germany, China, New Zealand, Japan, Russia, Belgium and Ukraine. 
  • To date, we've completed testing in over 50 countries at more than 6,000 sites, representing more than 80,000 patients. 
  • Download our infographic (PDF) 

Addressing the pain points of respiratory clinical trials.

Total of >175,000 clinical investigators •Total of >793,000 physicians •Total of >15 billion lab test results •Total of >16,000 protocols

Target lung disease patient populations for efficient recruitment

  • Access more than 150,000 asthma/COPD patients via partnership sites. 
  • Target experienced sites with high recruitment rates using Xcellerate®
  • Utilize specialist inflammatory biomarker analysis, e.g. eosinophil cationic protein and periostin

Leverage informatics to find respiratory investigators

  • Access more than 3,000 asthma and more than 2,500 COPD investigators worldwide
  • Select the highest-ranking investigators using our investigator performance database 

Coordinate with device & inhalation for lung administration routes

  • Partner with a single organization that offers device testing, in vitro diagnostics, clinical trials and inhalation routes of administration. 
  • Work with a global, dedicated inhalation team and facilities. 

Yield accurate data using centralized analysis and highly trained staff

  • Centralized objective endpoint analysis to reduce variability
  • Ensuring availability of appropriate instrumentation, and providing study-specific training on instrumentation use, and data collection, handling and interpretation

Optimize lung treatment pricing for successful market entry

  • Understand how devices patents (i.e. for inhalation devices) are different than pharma patents 
  • Use effective reimbursement strategies and patient follow-up for patients struggling with respiratory and lung disease

Access specialist pediatric investigators and sites

  • Expertise in pediatric protocol design and implementation
  • Identifying and supporting high-performing pediatric investigators
  • Formulating a pediatric development plan and engaging regulatory agency early in development process
  • Understanding patient challenges using voice of patient and/or parent insights, and incorporating into trial design
  • Site infrastructure to support patient and family needs

Let's start a conversation

Contact Us